TuHURA Biosciences (HURA) Expected to Release Earnings on Friday

TuHURA Biosciences (NASDAQ:HURA) is projected to release its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts expect TuHURA Biosciences to post ($0.57) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

TuHURA Biosciences Price Performance

Shares of TuHURA Biosciences stock opened at $1.52 on Thursday. The company’s fifty day simple moving average is $1.95 and its two-hundred day simple moving average is $1.99. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $3.43. The firm has a market cap of $96.87 million, a PE ratio of -2.81 and a beta of -0.23. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20.

Analysts Set New Price Targets

HURA has been the subject of a number of analyst reports. Citizens Jmp reiterated a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a report on Tuesday, August 18th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, TuHURA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies. TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.